- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05465902
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 Vaccines
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial.
The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral Vector COVID-19 vaccines (one or two doses) and have not been infected with COVID-19. All subjects will be evaluated for safety and immunogenicity after a single dose booster immunization with Recombinant COVID-19 variant Vaccine (Sf9 Cell) or inactivated COVID-19 vaccine (Vero cell) or mRNA vaccine or Viral Vector vaccine.
Study Overview
Status
Conditions
Detailed Description
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial.
The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral Vector COVID-19 vaccines (one or two doses) and have not been infected with COVID-19. All subjects will be evaluated for safety and immunogenicity after a single dose booster immunization with Recombinant COVID-19 variant Vaccine (Sf9 Cell) or inactivated COVID-19 vaccine (Vero cell) or mRNA vaccine or Viral Vector vaccine. The study plans to enroll about 600 subjects aged 18 years and above (subjects aged ≥ 60 years account for approximately 10%) that would be divided into three cohorts according to different primary vaccination: Inactivated COVID-19 vaccines cohort, mRNA COVID-19 vaccines cohort and Viral Vector COVID-19 vaccines cohort, with approximately 200 cases in each cohort. The subjects will be randomized to the Recombinant COVID-19 variant Vaccine (Sf9 Cell) group (test group) or the inactivated COVID-19 vaccine (Vero cell) group or mRNA vaccine or Viral Vector vaccine (control group) in a ratio of 1:1.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Michoacán De Ocampo
-
Morelia, Michoacán De Ocampo, Mexico, 58290
- Clínica de Enfermedades Crónicas y de Procedimientos Especiales, S.C.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Voluntarily sign the ICF approved by the Ethics Committee and agree to participate in the study before any study procedure.
- 2. Healthy males or females able to provide legal identification, aged 18 years and above at the time of signing ICF.
- 3. Subjects who have completed homologous primary vaccination with either Inactivated or mRNA or Viral Vector COVID-19 vaccines (full approval, CMA or EUA) and have the last dose administered 6 months ago or earlier from the date of signing the ICF for the study. Those who have received combined immunization with two doses of vaccines should be excluded.
- 4. Able to communicate well with the investigator, and able to understand and comply with the requirements of this clinical trial.
- 5. Males with female sexual partners or females of childbearing potential voluntarily take effective contraceptive methods from signing ICF to 3 months after the vaccination, including sexual abstinence or effective contraceptive measures (e.g., intrauterine or implanted contraceptive device, oral contraceptives, injected or implanted contraceptives, sustained-release topical contraceptives, intrauterine device (IUD), condoms (male), diaphragm, and cervical cap).
- 6. Axillary temperature <37.3℃.
Exclusion Criteria:
- 1. Positive SARS-CoV-2 RT-PCR at screening.
- 2. Prior medical history of Serve Acute Respiratory Syndromes (SARS), Middle East Respiratory Syndrome (MERS) and other human coronavirus infections or diseases.
- 3. Prior history or family history of convulsion, epilepsy, encephalopathy and psychosis.
- 4. Fear of needles.
- 5. Pregnant or lactating females or those who plan to become pregnant or donate eggs during study period.
- 6. Prior history of allergic reaction or anaphylaxis to any vaccine or its excipients, e.g., hypersensitivity, urticaria, serious eczema, dyspnea, laryngeal edema, and angioedema etc..
- 7. Prior use of any vaccine within 28 days before receiving this investigational vaccine or planning to use any vaccine other than this investigational vaccine during the study period.
- 8. Participation in studies of any other interventional device or drug within 28 days before the screening, or current treatment with other investigational drug(s) or within 5 half-lives after taking the last dose of the study drug.
- 9. Hereditary hemorrhagic tendency or coagulation dysfunction (e.g., clotting factors deficiency, coagulation disorders or platelet disorders), or a history of severe bleeding, or a history of massive bleeding after intramuscular injection or venipuncture, or a history of ecchymosis.
- 10. Known medical history or diagnosis confirming that subjects have diseases affecting immune system function, including cancer, congenital or acquired immunodeficiency (e.g., infection with Human Immunodeficiency Virus (HIV)), or uncontrolled autoimmune disease.
- 11. Serious or uncontrolled respiratory system disorders, cardiovascular disorders, nervous system disorders, blood and lymphatic system disorders, liver and kidney disorders, metabolism and skeletal disorders, etc. influencing study results evaluation at the investigator's discretion.
- 12. Asplenia or functional asplenia.
- 13. Long-term use (continuous use for ≥14 days) of immunosuppressants or other immunomodulators (e.g., glucocorticoids: prednisone or equivalents) within 6 months prior to administration of this investigational vaccine, except for topical medications (e.g., ointments, eye drops, inhalants or nasal sprays). And the topical medications should not exceed the recommended dose in the labels or induce any signs of systemic exposure.
- 14. Having received immunoglobulins and/or blood products within 3 months prior to administration of this investigational vaccine.
- 15. History of tuberculosis treatment or currently on antikoch's treatment for tuberculosis, whether pulmonary or extrapulmonary.
- 16. Suspected or known alcohol dependency or drug abuse, which may affect safety evaluation or subject's compliance at the investigator's discretion.
- 17. Planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits.
- 18. An employee of the study site, Sponsor and contract research organization (CRO) taking part in the study.
- 19. Other conditions unsuitable for this study at the investigator's discretion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inactivated COVID-19 vaccines cohort group 1
Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
|
1dose, Intramuscular Injection
|
Active Comparator: Inactivated COVID-19 vaccines cohort group 2
Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
|
1dose, Intramuscular Injection
|
Experimental: mRNA COVID-19 vaccines cohort group 1
Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment.
N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
|
1dose, Intramuscular Injection
|
Active Comparator: mRNA COVID-19 vaccines cohort group 2
Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment.
N=100 Intervention: mRNA COVID-19 vaccine (Moderna)
|
1dose, Intramuscular Injection
|
Experimental: Viral Vector COVID-19 vaccines cohort group 1
Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment.
N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
|
1dose, Intramuscular Injection
|
Active Comparator: Viral Vector COVID-19 vaccines cohort group 2
Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment.
N=100 Intervention: Viral Vector COVID-19 vaccine (AstraZeneca)
|
1dose, Intramuscular Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse drug reactions (ADRs)
Time Frame: Day 0-28 post-boost dose
|
Day 0-28 post-boost dose
|
GMT and SCR of specific neutralizing antibody (virus or pseudovirus) against SARS-CoV-2
Time Frame: Day 14 post-boost dose
|
Day 14 post-boost dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events (AEs)
Time Frame: Day 0-7 post-boost dose
|
Day 0-7 post-boost dose
|
Incidence of AEs
Time Frame: Day 0-28 post-boost dose
|
Day 0-28 post-boost dose
|
Incidence of serious adverse events (SAEs)
Time Frame: Day 0 through 6 months post-boost dose
|
Day 0 through 6 months post-boost dose
|
GMT and SCR of specific neutralizing antibody (virus or pseudovirus) against SARS-CoV-2
Time Frame: Day 28, month 3 and month 6 post-boost dose
|
Day 28, month 3 and month 6 post-boost dose
|
GMI of specific neutralizing antibody (virus or pseudovirus) against SARS-CoV-2
Time Frame: Day 14, Day 28, month 3 and month 6 post-boost dose
|
Day 14, Day 28, month 3 and month 6 post-boost dose
|
GMT, GMI and SCR of IgG antibodies against Vac2107 of SARS-CoV-2
Time Frame: Day 14, Day 28, month 3 and month 6 post-boost dose
|
Day 14, Day 28, month 3 and month 6 post-boost dose
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
GMT, GMI, and SCR of specific neutralizing antibody (virus or pseudovirus) against SARS-CoV-2 endemic variants
Time Frame: Day 14, Day 28, month 3 and month 6 post-boost dose
|
Day 14, Day 28, month 3 and month 6 post-boost dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JSVCT149
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Recombinant COVID-19 variant Vaccine (Sf9 Cell)
-
WestVac Biopharma Co., Ltd.Active, not recruiting
-
WestVac Biopharma Co., Ltd.WestVac Biopharma (Guangzhou) Co., Ltd.Recruiting
-
WestVac Biopharma Co., Ltd.Active, not recruiting
-
WestVac Biopharma Co., Ltd.CompletedCOVID-19 | SARS-CoV-2 PneumoniaChina
-
WestVac Biopharma Co., Ltd.Not yet recruiting
-
WestVac Biopharma Co., Ltd.West China HospitalCompletedCOVID-19 | SARS-CoV-2 InfectionChina
-
WestVac Biopharma Co., Ltd.CompletedCOVID-19 | SARS-CoV-2 InfectionPhilippines
-
Jiangsu Province Centers for Disease Control and...West China HospitalWithdrawn
-
WestVac Biopharma Co., Ltd.West China HospitalNot yet recruiting
-
WestVac Biopharma Co., Ltd.Not yet recruiting